Comparable outcomes of outpatient remdesivir and sotrovimab among high-risk patients with mild to moderate COVID-19 during the omicron BA.1 surge.

导出 LinkOut

翻译打印收藏纠错

作者： Supavit,Chesdachai ^[1] ; Christina G,Rivera ^[2] ; Kristin C,Cole ^[3] ; Hilary R,Teaford ^[2] ; Maria L,Gonzalez Suarez ^[4] ; Jennifer J,Larsen ^[5] ; Ravindra,Ganesh ^[6] ; Sidna,Tulledge-Scheitel ^[7] ; Raymund R,Razonable ^[8]

作者单位： Division of Public Health, Infectious Diseases, and Occupational Medicine, Mayo Clinic, 200 First St SW, Rochester, MN, 55905, USA. chesdachai.supavit@mayo.edu. ^[1] Department of Pharmacy, Mayo Clinic, Rochester, MN, USA. ^[2] Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA. ^[3] Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN, USA. ^[4] Department of Nursing, Mayo Clinic, Rochester, MN, USA. ^[5] Department of General Internal Medicine, Mayo Clinic, Rochester, MN, USA. ^[6] Department of Community Internal Medicine, Mayo Clinic, Rochester, MN, USA. ^[7] Division of Public Health, Infectious Diseases, and Occupational Medicine, Mayo Clinic, 200 First St SW, Rochester, MN, 55905, USA. razonable.raymund@mayo.edu. ^[8]

关键词 COVID-19 Outcome Remdesivir SARS-2-CoV Sotrovimab

主题词人类(Humans);门诊病人(Outpatients);腺苷一磷酸(Adenosine Monophosphate);丙氨酸(Alanine);抗体, 中和(Antibodies, Neutralizing)

DOI 10.1038/s41598-024-56195-y

PMID 38443438

发布时间 2024-04-26

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交